rs2066808 — IL23A

IL23A rs2066808 — A Genetic Switch in the Psoriasis Cytokine Engine

The rs2066808 variant lies within an intron of the STAT2 gene but sits immediately adjacent to IL23A on chromosome 12q13.3, and is the primary genome-wide association signal¹¹ genome-wide association signal
A variant reaching p < 5×10⁻⁸ in a population-scale disease study for the IL23A locus in psoriasis. IL23A encodes the p19 subunit — the half of interleukin-23 that is unique to IL-23 and absent from the closely related cytokine IL-12, which shares the p40 subunit. Because IL-23 is the master driver of Th17 cell differentiation²² Th17 cell differentiation
Th17 cells produce IL-17A and IL-17F, which stimulate keratinocyte hyperproliferation, a hallmark of psoriatic plaques, variants at this locus have direct clinical relevance not only for predicting psoriasis risk but also for understanding why anti-IL-23 biologics are among the most effective treatments available.

The Mechanism

The G allele at rs2066808 is an intronic variant within the STAT2/IL23A genomic neighbourhood; it does not change any amino acid in the IL-23 p19 protein. Instead, it acts as a regulatory or linkage tag³³ linkage tag
Variants in strong LD with a functional regulatory element will appear as GWAS hits even if they are not themselves the causal change for one or more functional elements that increase IL23A transcription in immune cells — particularly dendritic cells and macrophages in inflamed skin. Studies of uninvolved versus involved psoriatic skin found that IL23A is among the most significantly upregulated genes at active plaques (p < 10⁻⁹), making this locus functionally important beyond its statistical association. The elevated IL-23 drives naïve T cells toward the Th17 fate, causing sustained production of IL-17A, IL-17F, and IL-22, which together stimulate keratinocytes to proliferate abnormally and recruit additional neutrophils and inflammatory cells. This self-amplifying loop underlies both the chronic skin plaques of psoriasis and the synovitis of psoriatic arthritis.

The Evidence

The initial discovery came from a 2009 genome-wide scan⁴⁴ 2009 genome-wide scan
1,409 cases and 1,436 controls from a US/European population, followed up in 5,048 cases and 5,041 controls published in Nature Genetics, which genotyped 438,670 SNPs and identified rs2066808 as one of seven independent psoriasis risk loci (OR=1.34, combined p=1×10⁻⁹). The risk allele frequency in controls was approximately 7%, meaning the G allele is a true minor allele in most non-African populations. A subsequent independent cohort study⁵⁵ independent cohort study
Arthritis UK-funded case-control study of psoriatic arthritis specifically confirmed the association in psoriatic arthritis (p=9.1×10⁻⁷), establishing that this locus influences joint disease as well as skin disease.

Additional replication came from a Romanian cohort⁶⁶ a Romanian cohort
128 PsA patients and 116 healthy controls, with haplotype analysis of rs2066808 and rs11171806 confirming that carriers of the A allele (the major allele) were more frequent among PsA patients, and a multi-phenotype study⁷⁷ multi-phenotype study
Combined analysis of psoriasis severity, PsA, and type 2 diabetes in European cohorts linking IL23A variation to both psoriatic disease severity and metabolic comorbidities. Intriguingly, a Chinese Han study⁸⁸ Chinese Han study
206 IDD patients sequenced for IL23A and IL23R found rs2066808 associated with multiple sclerosis and other inflammatory demyelinating diseases, consistent with IL-23's broader role in CNS autoimmunity. The variant has also been associated with premature coronary artery disease⁹⁹ premature coronary artery disease
GEA study of 1,160 Mexican patients with CAD onset before 55 in men / 65 in women under a recessive model (GG versus AA+AG: OR=4.57), linking chronic IL-23-driven inflammation to accelerated atherosclerosis.

The biological relevance of this locus is powerfully validated by the therapeutic success of IL-23 p19 inhibitors. Guselkumab (approved 2017) and risankizumab (approved 2019) both selectively block the p19 subunit encoded by IL23A, achieving PASI-90 response rates¹⁰¹⁰ PASI-90 response rates
90% reduction in Psoriasis Area and Severity Index score — a stringent measure of near-complete clearance exceeding 70–75% in randomised trials, far outperforming earlier biologics.

Practical Actions

For individuals carrying the G allele — whether heterozygous AG or the rare homozygous GG — the key actions centre on early recognition of psoriatic disease, lifestyle factors that modulate IL-23 activity, and informed conversations with dermatologists or rheumatologists if symptoms arise. Carrying the G allele does not guarantee psoriasis, but it shifts the probability meaningfully, particularly in the context of known triggers such as streptococcal infection, stress, certain medications (beta-blockers, lithium, antimalarials), obesity, and smoking.

Dietary patterns that reduce systemic inflammation — particularly reducing ultra-processed food, refined carbohydrates, and excess saturated fat — may help lower baseline IL-23 signalling, though no intervention trial has directly targeted IL23A carriers. Omega-3 fatty acids (EPA and DHA from oily fish or supplements) have documented anti-Th17 effects and have been associated with reduced psoriasis severity in observational studies.

If psoriasis or psoriatic arthritis develops, carrying a confirmed IL23A risk allele provides biological rationale for discussing IL-23-targeted biologics (guselkumab, risankizumab, tildrakizumab) with your dermatologist or rheumatologist, since you carry a variant in the very gene encoding the cytokine these drugs block.

Interactions

The rs2066808 locus interacts within the IL-23 pathway with IL12B (rs3212227), which encodes the shared p40 subunit of both IL-12 and IL-23. Carrying risk alleles at both loci may compound Th17 polarisation. IL23R (rs11209026) encodes the receptor that IL-23 signals through; the rs11209026 R381Q protective allele reduces receptor sensitivity and is associated with substantially lower psoriasis and Crohn's disease risk — effectively acting as a counterweight to IL23A risk alleles. The rs2066808 variant is in moderate linkage disequilibrium with rs11171806, another IL23A region variant, forming a haplotype block that confers higher PsA risk than either variant alone in Romanian and other European cohorts.